Akero Therapeutics (AKRO): Volume dana dhuwit perusahaan

Logo grafis akerotx.com (AKRO)

The current cash position demonstrates the financial stability of Akero Therapeutics (AKRO). The company relies on a team of top biochemists whose motivation is secured through stock option programs. This potential is bolstered by the development of efruxifermin to combat NASH. Meanwhile, the patent protection of new molecules promises years of excess profits from liver therapy. The 0.72 metric determines the status of the issuer's liquidity parameter.

Volume dana dhuwit perusahaan: Akero Therapeutics, Inc. (AKRO) kanggo 04.07.2022 - 20.12.2025

Rincian metrik keuangan lan pasar Akero Therapeutics, Inc. (AKRO)

- nilai saham lan prakiraan konsensus rega:
Analisis kabeh metrik perusahaan:Akero Therapeutics AKRO
Produk mawa merek Akero

To assess the financial stability of Akero Therapeutics (AKRO), it is critical to monitor the liquidity reserve that ensures seamless interaction with contract manufacturers within its asset-light model. By analyzing the volume of highly liquid cash assets, an investor determines the company's ability to fund operating activities without external borrowing, noting that excessive reserve accumulation may reduce the overall return on equity during a shift in the market cycle.

Pesaing langsung

Dana dhuwit perusahaan ascendispharma.com (ASND)|Dhuwit awis perusahaan madrigalpharma.com MDGL|Volume dana dhuwit perusahaan CORT (Corcept Therapeutics Inc.)|Sisa dhuwit perusahaan RYTM|metsera.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan MoonLake Corp|CRNX: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan NewAmsterdam Pharma|SLNO (Soleno Therapeutics Corp) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan Amicus Pharma (FOLD)|Dhuwit awis perusahaan ETNB (89bio Corp)|Aset likuid perusahaan Agios Pharmaceuticals|Structure Pharma - Dhuwit awis perusahaan|MDXG: Dhuwit awis lan setara dhuwit awis perusahaan|RZLT: Dhuwit awis perusahaan|LXRX (Lexicon Pharma) - Dhuwit awis lan setara dhuwit awis perusahaan|MBX: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Altimmune, Inc. (ALT)|Dhuwit awis perusahaan AARD|Dana dhuwit perusahaan SGMT|Volume dana dhuwit perusahaan BIOA|Aset likuid perusahaan Biomea Fusion|Dana dhuwit perusahaan Quince Therapeutics QNCX|Volume dana dhuwit perusahaan Fractyl Health, Inc GUTS|VTVT: Dhuwit awis perusahaan|Cadangan dhuwit perusahaan Agape ATP|PLUR (Pluri) - Dhuwit awis perusahaan|SYBX - Aset likuid perusahaan|Dana dhuwit perusahaan Lipocine Corp|Volume dana dhuwit perusahaan matinasbiopharma.com|Dana dhuwit perusahaan Spruce Biosciences, Inc. (SPRB)|Gunggung dana dhuwit perusahaan GLTO|Carmell Corporation - Dhuwit awis perusahaan|LUMO - Dhuwit awis perusahaan|ONVO - Dana dhuwit perusahaan|Sisa dhuwit perusahaan RDUS (Radius Health)